The antiamnesic and neuroprotective activities of the new aminotetrahydrofuran derivative tetrahydro-N,N-dimethyl-5,5-diphenyl-3-furanmethanamine hydrochloride (ANAVEX1-41), a nonselective muscarinic receptor ligand and s 1 protein activator, were examined in mice injected intracerebroventricularly with amyloid b [25] [26] [27][28][29][30][31][32][33][34][35] ) peptide (9 nmol). Ab 25-35 impaired significantly spontaneous alternation performance, a spatial working memory, and passive avoidance response. When ANAVEX1-41 (1-1000 mg/kg i.p.) was administered 7 days after Ab 25-35 , ie, 20 min before the behavioral tests, it significantly reversed the Ab 25-35 -induced deficits, the most active doses being in the 3-100 mg/kg range. When the compound was preadministered 20 min before Ab 25-35 , ie, 7 days before the tests, it prevented the learning impairments at 30-100 mg/kg. Morphological analysis of corticolimbic structures showed that Ab 25-35 induced a significant cell loss in the CA1 pyramidal cell layer of the hippocampus that was prevented by ANAVEX1-41 (100 mg/kg). Increased number of glial fibrillary acidic protein immunopositive cells in the retrosplenial cortex or throughout the hippocampus revealed an Ab 25-35 -induced inflammation that was prevented by ANAVEX1-41. The drug also prevented the parameters of Ab 25-35 -induced oxidative stress measured in hippocampus extracts, ie, the increases in lipid peroxidation and protein nitration. ANAVEX1-41, however, failed to prevent Ab 25-35 -induced caspase-9 expression. The compound also blocked the Ab 25-35 -induced caspase-3 expression, a marker of apoptosis. Both the muscarinic antagonist scopolamine and the s 1 protein inactivator BD1047 prevented the beneficial effects of ANAVEX1-41 (30 or 100 mg/kg) against Ab 25-35 -induced learning impairments, suggesting that muscarinic and s 1 targets are involved in the drug effect. A synergic effect could indeed account for the very low active doses measured in vivo. These data outline the therapeutic potential of ANAVEX1-41 as a neuroprotective agent in Alzheimer's disease.
INTRODUCTION
Alzheimer disease (AD) is an irreversible, progressive and degenerative disorder damaging the higher structures of the brain (Selkoe, 1989 (Selkoe, , 2004 . It is actually incurable, as the available treatments, acetylcholinesterase inhibitors or a N-methyl-D-aspartate receptor antagonist with neuroprotective potential, memantine, are mainly symptomatic. The pathological cleavage of amyloid precursor protein (APP) is responsible for the accumulation of amyloid-b (Ab) proteins, aggregating into fibrillar oligomers and generating amyloid deposits that, in turn, form the senile plaques (Selkoe, 1989 (Selkoe, , 2004 . Oligomers of Ab peptides are considered as the main factor mediating the devastating neurotoxicity observed in AD. Ab peptides vary in length from 40 to 43 amino acids, Ab 1-42 occurring more frequently and forms fibrillar aggregates far more readily than Ab 1-40 or Ab (Selkoe, 1989) . Minor fragments were also identified including the highly toxic Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] peptide (Kubo et al, 2002; Gruden et al, 2007) . The Ab-mediated toxicity follows a very complex pattern. Ab oligomers form Ca 2 + permeable pores on plasma membranes and interact with intracellular organelles regulating calcium homeostasis, the endoplasmic reticulum (ER) and mitochondria (Abramov et al, 2004) , provoking a massive oxidative stress and induction of neuronal apoptotic death. Ab proteins are also responsible for a generalized inflammatory response in brain structures associated with production of cytokines by activated astroglia and microglia (Frederickson, 1992) and exacerbated excitotoxic processes (Mattson et al, 1992) .
Moreover, toxicity of Ab has recently been shown to be highly dependent on the aggregation species (Chafekar et al, 2008) . Ab can exist in different assembly states and apart from the monomeric and mature fibrillar stages, different intermediate species have been identified, such as low molecular weight oligomers, larger globular oligomers, and protofibrils. This is true for Ab or Ab 1-42/3 but also for Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] peptide. These different species greatly differ in their neurotoxic potential and molecular mechanism mediating the toxicity. For instance, impairment of longterm potentiation (Walsh et al, 2002) and ER stress (Chafekar et al, 2007) may be mediated by small oligomers, whereas the neuroinflammatory response may rather involve fibrillar Ab (Eikelenboom et al, 2002) . Preliminary observations of the laboratory showed that after in vitro aggregation, Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] peptide exist in these different species including small oligomers, amorphous oligomers, and fibrillar forms (S Marchal, L Givalois, T Maurice, unpublished work) .
We described the nontransgenic model of AD induced in rodents by injection into the lateral ventricle of aggregated Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] peptide (Maurice et al, 1996; Delobette et al, 1997) . The morphological and biochemical characterization of amyloid toxicity induced by Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] has been subsequently analyzed in details. Ab 25-35 induces brain inflammation, oxidative stress, activation of proapoptotic caspases, impairment of long-term potentiation, cell loss in the hippocampus, and memory impairments (Stepanichev et al, 2004 (Stepanichev et al, , 2006 Meunier et al, 2006) . Recently, it was also observed that Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] injection activates the glycogen synthase kinase-3b, involved in cell survival regulation, T-phosphorylation and APP processing, suggesting that acute Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] injection results in production and seeding of endogenous Ab 1-40/42 and T-phosphorylation (Klementiev et al, 2007) . The model therefore appears as highly suitable to analyze the putative antiamnesic and neuroprotective activity of drugs with potential interest in AD, as recently used by several authors (Fang and Liu, 2006; Kuboyama et al, 2006; Meunier et al, 2006; Um et al, 2006; Alkam et al, 2007) .
The s 1 protein has only recently been identified as a chaperone protein located on membranes forming focal contacts between the ER and mitochondria (Hayashi and Su, 2007) . In basal conditions, the s 1 protein forms a complex with the other chaperone glucose-regulated protein 78 kDa (GRP78/BiP). Upon ER Ca 2 + depletion or by ligand stimulation, the s 1 protein dissociates from GRP78/BiP, leading to a prolonged Ca 2 + signaling into mitochondria by IP 3 receptors (Hayashi and Su, 2007) . Under intracellular Ca 2 + signaling disruption and subsequent ER stress, the s 1 protein translocates, to reach plasma membrane, recruiting Ca 2 + -dependent intracellular cascades (Morin-Surun et al, 1999) . On the plasma membrane, it contributes to form or modify the composition of lipid-rich microdomains, socalled lipid rafts Su, 2001, 2003) . Increasing or activating s 1 proteins is expected to counteract ER stress response, whereas decreasing or inactivating them would enhance apoptosis (Hayashi and Su, 2007) . Modifying s 1 protein activation using selective activators/agonists therefore mediates a unique pharmacological action on Ca 2 + homeostasis and signal transduction pathways, which has proven to allow an effective neuroprotection against several kinds of insults, including excitotoxicity, oxidative stress, and amyloid toxicity (for reviews, see Maurice et al, 2006; Monnet and Maurice, 2006) . Indeed, preliminary experiments showed that, in vitro, the selective s 1 activators PRE-084 and MR-22 attenuate the Ab 25-35 -induced expression of the proapoptotic protein Bax and neuronal death in rat cortical cultures (Marrazzo et al, 2005) . We reported that, in vivo, PRE-084 prevents the Ab 25-35 -induced oxidative stress and learning impairments in mice (Meunier et al, 2006) . ANAVEX1-41 is a new aminotetrahydrofuran derivative (Vamvakides, 2002; Espallergues et al, 2007 ) acting as a s 1 protein activator, with a high affinity (44 nM) and selectivity. The CEREP profile of the compound showed that it also presents nanomolar affinities (18-114 nM) for muscarinic receptors (M 1 4M 3 , M 4 4M 2 ), some low micromolar affinity for sodium channel site 2, and negligible interaction with 60 other receptor and enzyme assays (data not shown). Its molecular profile is coherent with its antiamnesic and antidepressant effects (Espallergues et al, 2007) . In this study, we analyzed its antiamnesic and neuroprotective potentials against Ab 25-35 -induced toxicity in mice. Learning deficits were measured using the spontaneous alternation test measuring spatial working memory and passive avoidance response measuring longterm contextual memory. The Ab 25-35 -induced toxicity was also analyzed at the morphological and biochemical levels. Finally, the involvement of the s 1 protein or muscarinic receptors was examined using pretreatments with a selective antagonist, BD1047 or scopolamine, respectively.
MATERIALS AND METHODS

Animals
Male Swiss mice (Depré, St-Doulchard, France), aged 7 weeks and weighing 32 ± 2 g, were used in this study. Animals were housed in plastic cages in groups. They had free access to food and water, except during behavioral experiments, and they were kept in a regulated environment (23 ± 11C, 40-60% humidity) under a 12 h light/dark cycle (light on at 0800 hours). Experiments were carried out between 0900 and 1700 hours, in an experimental room within the animal facility. Mice were habituated 30 min before each experiment. All animal procedures were conducted in strict adherence of European Union Directive of 24 November 1986 (86-609) .
Drugs
Tetrahydro-N,N-dimethyl-5,5-diphenyl-3-furanmethanamine hydrochloride (ANAVEX1-41, formerly AE14) was synthesized in the laboratory (Anavex Life Sciences, Pallini, Greece). N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(dimethylamino)ethylamine dihydrobromide (BD1047) was from Tocris Bioscience (Bristol, UK). All other materials, including scopolamine hydrobromide, xylenol orange, and cumene peroxide, were purchased from Sigma-Aldrich (Saint Quentin Fallavier, France). Drugs used for in vivo Protection by ANAVEX1-41 against Ab 25-35 toxicity V Villard et al experiments were solubilized in physiological saline solution and administered intraperitoneally (i.p.) in a volume of 100 ml per 20 g body weight. The Ab 25-35 peptide (Gly-SerAsn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met, Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] ) and scrambled Ab 25-35 peptide (Ala-Lys-Ile-Gly-Asn-Ser-Ile-Gly-Leu-MetGly, ScAb) were from NeoMPS (Strasbourg, France). They were dissolved in sterile bidistilled water at a concentration of 3 mg/ml and stored at À201C until use. Before injection, peptides were aggregated by incubation at 3 mg/ml in sterile bidistilled water at 371C for 4 days. They were administered intracerebroventricularly (i.c.v.) in a final volume of 3 ml per mouse, as previously described (Maurice et al, 1996 (Maurice et al, , 1998 .
Spontaneous Alternation Performances
Each mouse, naive to the apparatus, was placed at the end of one arm in a Y-maze (three arms, 40 cm long, 1201 separate) and allowed to move freely through the maze during a single 8-min session. The series of arm entries, including possible returns into the same arm, was recorded visually. An alternation was defined as entries into all three arms on consecutive trials. The number of the total possible alternations was therefore the total number of arm entries minus two and the percentage of alternation was calculated as (actual alternations/total possible alternations) Â 100. Animals performing less than eight arm entries in 8 min were discarded (ie, less than 5% of animals).
Step-Down Type Passive Avoidance Test
The apparatus consisted of a transparent acrylic cage (30 Â 30 Â 40 cm high) with a grid-floor, inserted in a soundproof outer box (35 Â 35 Â 90 cm high). A 15 W lamp lighted the cage during the experimental period. A wooden platform (4 Â 4 Â 4 cm) was fixed at the center of the gridfloor. Intermittent electric shocks (1 Hz, 500 ms, 40 V DC) were delivered to the grid-floor using an isolated pulse stimulator (Model 2100; AM Systems, Everett, WA, USA). The test consisted of two training sessions, at 90-min time interval, and a retention session, carried out 24 h after the first training. During training sessions, each mouse was placed on the platform. When it stepped down and placed its four paws on the grid-floor, shocks were delivered for 15 s.
Step-down latency and the numbers of vocalizations and flinching reactions were measured. Shock sensitivity was evaluated by adding these two numbers. None of the treatments used in this study significantly affected the shock sensitivity. Animals that stepped down before 3 s has elapsed or that did not step down within 30 s were discarded (ie, less than 5% of the mice). Animals, which did not step down within 60 s during the second session, were considered as remembering the task and taken off, without receiving further electric shocks. The retention test was performed in a similar manner as training, except that the shocks were not applied to the grid-floor. Each mouse was again placed on the platform, and the latency was recorded, with an upper cutoff time of 300 s. Two parametric measures of retention were analyzed: the latency and the number of animals reaching the avoidance criterion, defined as correct if the latency measured during the retention session was greater than threefold the latency showed by the animal during the second training session and, at least, greater than 60 s.
Histology
Each mouse was anesthetized by intramuscular (i.m.) injection of ketamine, 80 mg/kg, and xylazine, 10 mg/kg, and quickly transcardially perfused with 50 ml of saline solution followed by 50 ml of paraformaldehyde 4%. Brains were removed and kept overnight in the fixative solution. They were cut in coronal sections (30 mm thickness) using a vibratome (Leica VT1000 S). Serial sections were selected to include the hippocampus formation and placed in gelatincoated glass strip. Sections were stained with 0.2% cresyl violet reagent (Sigma-Aldrich), then dehydrated with graded ethanol, treated with toluene and mounted with DePeX medium (BDH Laboratories, Poole, UK). Examination of the CA1 area was performed using a light microscope (Dialux 22, Leitz), slices being digitalized through a CCD camera (Sony XC-77CE) with the NIH ImageJ software, to easily process CA1 measurement and pyramidal cells counts. Data were calculated as average of six slices and expressed as number of viable CA1 pyramidal cells per millimeter for each group.
Immunohistochemistry
Mice were anesthetized by i.m. injection of ketamine 10% and xylazine 2%, perfused transcardially with 50 ml of saline solution followed by 50 ml of paraformaldehyde 4%. Brains were removed and kept overnight in the fixative solution. Brain sections were cut in coronal sections (30 mm thickness) using a vibratome (Leica VT1000 S). Analysis of the glial response to neurodegeneration was carried out by immunolabeling sections, with mouse monoclonal antiglial fibrillary acidic protein (GFAP; Sigma-Aldrich; 1 : 1000).
Lipid Peroxidation Measures
Mice were killed by decapitation and brains were rapidly removed, weighed, and kept in liquid nitrogen until assayed. After thawing, brains were homogenized in cold methanol (1 : 10, w/v), centrifuged at 1000 g during 5 min and the supernatant collected. Homogenate was added to a solution containing FeSO 4 1 mM, H 2 SO 4 0.25 M, xylenol orange 1 mM, and incubated for 30 min at room temperature. Absorbance was measured at 580 nm (A 580 1), and 10 ml of cumene hydroperoxide (CHP) 1 mM was added to the sample and incubated for 30 min at room temperature, to determine the maximal oxidation level. Absorbance was measured at 580 nm (A 580 2). The level of lipid peroxidation was determined as CHP equivalents according to: CHP equiv. ¼ A 580 1/A 580 2 Â (CHP (nmol)) Â dilution, and expressed as CHP equiv. per wet tissue weight.
Western Blotting
For determination of protein nitration levels, mice were decapitated 5 days after Ab peptide injection. The hippocampus were removed on ice-cold glass plate and stored at À801C. The hippocampus tissues were homoProtection by ANAVEX1-41 against Ab 25-35 toxicity V Villard et al genized in ice-cold 20 mM Tris-HCl extraction buffer, pH 7.6, containing 150 mM NaCl, 2 mM EDTA, 50 mM sodium fluoride, 1 mM sodium vanadate, 1% NP-40, 1% sodium deoxycholate, 0.1% sodium dodecylsulfate (SDS), 1 mg/ml pepstatin, 1 mg/ml aprotinin, and 1 mg/ml leupeptin. Equal amounts of protein, 40 mg per lane, were resolved by a 10% SDS-polyacrylamide gel electrophoresis, and then transferred electrophoretically to a polyvinylidene difluoride membrane (Millipore, Billerica, MA). Membranes were incubated in 3% skimmed milk in a washing buffer, Tris-buffered saline containing 0.05% (v/v) Tween 20, for 2 h at room temperature. Then, membranes were incubated at 41C overnight with an antinitrotyrosine mouse clone1A6 (Upstate Cell Signaling, Lake Placid, USA; 1 : 1000) or with goat anti b-actin primary antibody (Santa Cruz Biotechnology, Santa Cruz, CA; 1 : 100). After a wash, membranes were incubated with horseradish peroxidase-conjugated antimouse IgG (Sigma-Aldrich; 1 : 2000). Peroxidase activity was revealed by using enhanced chemiluminescence (ECL) reagent. Then, intensity of peroxidase activity was semiquantified using the ImageJ software. Results were corrected with the corresponding b-actin level and expressed as percentage of control group data.
For determination of GFAP, caspase-3 or caspase-9 expression, mice were decapitated 7 days after Ab peptide injection. The hippocampi were removed on ice-cold glass plate and stored at À801C. The hippocampus tissues were homogenized in ice-cold extraction buffer containing SDS 2% and proteases inhibitors (Roche). Equal amounts of protein, 40 mg per lane, were resolved by a 12% SDS-polyacrylamide gel electrophoresis, and then transferred electrophoretically to a nitrocellulose blot membrane (Schleicher Schuell 0.45 mm). The membranes were then blocked during 30 min at room temperature with 5% skim milk in Tris-buffered saline 20 mM (pH 7.6) containing 0.1% Tween 20 (TBS-T). The membranes were incubated at 41C overnight with a mouse monoclonal anti-GFAP antibody (Sigma-Aldrich; 1 : 2000), or rabbit anticaspase-3 or rabbit anticaspase-9 antibody (Cell Signaling Technology; 1 : 1000 each), rinsed for 30 min in TBS-T and then incubated for 2 h with a goat antimouse or antirabbit secondary antibody (Sigma-Aldrich; 1 : 2000 each). Peroxidase activity was revealed by using ECL reagent. Then, intensity of peroxidase activity was semiquantified using the ImageJ software. Results were normalized to control values (anti b-tubulin; Sigma-Aldrich; 1 : 5000).
Statistical Analyses
Biochemical and behavioral data were expressed as mean ± SEM, except step-down latencies expressed as median and interquartile range. They were analyzed using one-way ANOVA (F-values), followed by the Dunnett's post hoc multiple comparison test. Passive avoidance latencies were analyzed a Kruskal-Wallis nonparametric ANOVA (H-values), as upper cutoff times were set, followed by the Dunn's multiple comparison test. The level of statistical significance was po0.05.
RESULTS
Antiamnesic Effects of ANAVEX1-41 Against Ab 25-35 -Induced Learning Impairments
In the first series of experiments, the antiamnesic effects of ANAVEX1-41 was examined in mice centrally injected 7 days before with scrambled Ab (ScAb) or Ab 25-35 peptide. The spatial working memory was first examined in the Y-maze test, animals receiving ANAVEX1-41 20 min before the session. As shown in Figure 1a , the central administration of ScAb peptide or the subsequent i.p. treatment with ANAVEX1-41, in the 1-1000 mg/kg dose range, failed to change the spontaneous alternation performance that was in the 65-70% range (Fo1). The treatments also did not affect the total number of arm entries (Fo1; Figure 1b) . When mice were treated with Ab 25-35 , the alternation performance decreased highly significantly to 53% and the ANAVEX1-41 treatment reversed the deficit (F (8,145) ¼ 4.41, po0.0001; Figure 1c) . The compound showed a significant effect at the dose of 3 mg/kg and the improvement remained significant up to the highest dose tested. The most effective dose appeared to be 10 mg/kg. Neither the Ab 25-35 , nor the ANAVEX1-41 treatments affected the number of arm entries (F (8,145) ¼ 1.62, p40.05; Figure 1d ).
The long-term contextual memory was evaluated using the step-down type passive avoidance procedure. Animals were tested 8 days after the central administration of ScAb or Ab 25-35 peptide and ANAVEX1-41 compound was administered 20 min before the first training session. The retention test was performed on day 9 after the peptide administration. As shown in Figure 2a and b, the ScAb peptide or the subsequent treatment with ANAVEX1-41 in the 1-1000 mg/kg dose range, failed to affect the latency (H ¼ 2.98, p40.05; Figure 2a ) or percentage of animal-tocriterion that were in the 60-80% range (Figure 2b ). In particular, the compound failed to show memory enhancing effect, as compared with V-treated animals. However, it must be noted that in procedures adapted to the measure of memory enhancing effects, the intensity of footshocks is lower than used in the present experiment. The central injection of Ab 25-35 peptide led to highly significant decreases in latency (H ¼ 27.72, po0.001; Figure 2c ) and percentage of animals-to-criterion (Figure 2d ). The ANAVEX1-41 treatment resulted in a bell shaped but highly significant reversion of the deficits. Both parameters revealed an active dose range of 1-100 mg/kg.
Neuroprotective Effects of ANAVEX1-41 Against the Ab 25-35 -Induced Learning Deficits
The neuroprotective effects of ANAVEX1-41 were first analyzed on the appearance of Ab 25-35 -induced learning deficits. The drug was administered in the same, 1-1000 mg/kg i.p., dose range and only once, 20 min before the i.c.v. administration of the peptide. We previously reported that such procedure is highly effective for mixed cholinergic/s 1 compounds (Meunier et al, 2006) . The pretreatment with ANAVEX1-41 resulted, 7 days after in a bell shaped but significant prevention of the Ab 25-35 -induced spontaneous alternation impairments (F (8,145) ¼ 3.40, po0.01; Figure 3a) . The active doses of compound were in the 10-100 mg/kg range. No effect was observed in terms of number of arm entries (F (8,145) ¼ 1.64, p40.05; Figure 3b ). The ANAVEX1-41 pretreatment also resulted in a significant prevention of the passive avoidance deficits, both in terms of latencies (H ¼ 45.2, po0.0001; Figure 3c ) and number of animals-tocriterion (Figure 3d ). In this procedure, however, the active dose range was 30-300 mg/kg.
Neuroprotective Effects of ANAVEX1-41 Against Ab 25-35 -Induced Toxicity
Morphological validation of the protective effect of ANAVEX1-41 was examined using the most active dose of compound, 100 mg/kg. The pyramidal cell layer of the hippocampus is highly sensitive to the amyloid toxicity observed after Ab 25-35 peptide injection in mice. We analyzed the number of viable cells in CA1 hippocampus area using cresyl violet staining (Figure 4) . The Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] injection induced a À24.6% decrease in the number of viable cells in Ab 25-35 -treated mice (F (3,20) ¼ 7.68, po0.01; Figure 4c and e) as compared with ScAb-treated mice (Figure 4a and e) . In the same mice, no significant effect was measured in the CA3 area: 192±6 cell per field (n ¼ 6) for the ScAb group vs 187 ± 10 cell per field (n ¼ 6, p40.05) for the Ab 25-35 group. The ANAVEX1-41 treatment failed to affect the number of viable cells in the ScAb-treated group (Figure 4b and e) , but significantly attenuated the diminution observed after Ab 25-35 treatment (Figure 4d and e) .
The extent of brain inflammation after Ab 25-35 and subsequent ANAVEX1-41 treatment was analyzed by measuring reactive astrocytes using GFAP immunohistolabeling ( Figure 5) . As the i.c.v. injection is expected to provoke by itself a massive glial reaction, ScAb-treated groups were compared with animals receiving only the i.p. treatment with vehicle solution (Figure 5a , g, m and s) or ANAVEX1-41 (100 mg/kg; Figure 5b , h, n and t). Several Ab 25-35 injection, however, provoked after 7 days a marked increase in the number of labeled astrocytes and in their branching, resulting in densification of astrocytic clusters. This was observed in the retrosplenial cortex (Figure 5e ), but not in the parietal area (Figure 5k ). The ANAVEX1-41 treatment resulted in a blockade of Ab 25-35 -induced increase of GFAP labeling (Figure 5f ). In the hippocampus, astrocytes were regularly disseminated throughout the oriens and stratum radiatum layers surrounding the pyramidal cell layers (indicated by asterisks), at both the CA1 and CA3 levels (Figure 5m (Figure 5r and x) . Quantification of the increase in GFAP expression was performed in the hippocampus by western blotting. As shown in Figure 6 , the ScAb i.c.v. treatment or/and the ANAVEX1-41 i.p. treatment were without effect on GFAP expression. The Ab 25-35 treatment significantly increased GFAP expression and this increase was blocked by ANAVEX1-41 (F (5,49) ¼ 5.59, po0.001; Figure 6 ). These data strengthened the qualitative immunohistochemical observations. Several biochemical parameters of amyloid toxicity were also analyzed in the hippocampus extracts to validate the neuroprotective activity of ANAVEX1-41. First, amyloid peptides, and particularly Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , induce a massive oxidative stress in forebrain structures. We therefore analyzed in the levels of lipid peroxidation (Figure 7a ) and protein nitration (Figure 7b ) and induction of caspase-9 expression, a marker of mitochondrial damage (Figure 7c ). Protection by ANAVEX1-41 against Ab 25-35 toxicity V Villard et al Second, amyloid toxicity results in cell death through caspase-dependent apoptosis pathways. We therefore measured the induction of caspase-3 expression (Figure 7d ). Ab 25-35 induced a + 117% increase in the level of peroxidized lipids that could be measured in the hippocampus (F (6,82) ¼ 8.07, po0.0001; Figure 7a) . ANAVEX1-41, tested in the 10-1000 mg/kg i.p. dose range, highly significantly, but in a U-shaped manner, prevented the Ab 25-35 -induced increase in lipid peroxidation. The protective effect was measured at 30 and 100 mg/kg (Figure 7a) . The western blot analysis of protein nitration revealed only a single band for nitrated proteins at the size of 70 kDa (Figure 7b , see Supplementary Figure 1 for the whole blot). Ab 25-35 induced a + 30% increase in nitrotyrosine immunoreactivity (F (3,23) ¼ 8.99, po0.001; Figure 7b ). The pretreatment with ANAVEX1-41, 100 mg/kg i.p., tended to decrease the level of nitrotyrosine immunoreactivity in ScAb-treated mice (À19%, p40.05) but highly significantly prevented the Ab 25-35 -induced increase (Figure 7b) . The western blot analysis of caspase-9 expression revealed only a single band at the size of 49 kDa that corresponded to procaspase-9 (Figure 7c ). Ab 25-35 induced a + 38% increase in caspase-9 expression (F (3,51) ¼ 4.13, po0.05; Figure 7c ). The pretreatment with ANAVEX1-41, 100 mg/kg i.p., failed to affect caspase-9 expression in ScAb-or Ab 25-35 -treated animals ( Figure 7c) . The western blot analysis of caspase-3 expression revealed only a single band at the size of 35 kDa that corresponded to the cleaved form of caspase-3 (Figure 7d ). Ab 25-35 induced a + 32% increase in caspase-3 induction (F (3,34) ¼ 4.31, po0.05; Figure 7d ). The pretreatment with ANAVEX1-41, 100 mg/kg i.p., significantly prevented the Ab 25-35 -induced increase (Figure 7d) . However, the treatment also resulted in a significant increase in the level of caspase-3 induction in ScAb-treated mice ( + 20%, po0.05; Figure 7d ).
Involvement of (i) Muscarinic receptors and (ii) r 1 Protein in the Neuroprotective Effect of ANAVEX1-41
The compound is equally active, with binding affinities in the 18-114 nM range, on muscarinic M 1 -M 4 receptors and the s 1 protein (Espallergues et al, 2007) . To determine Protection by ANAVEX1-41 against Ab 25-35 toxicity V Villard et al whether both pharmacological targets are involved in the protective effects of the compound, we coadministered: (i) the muscarinic receptor antagonist scopolamine (0.5 mg/kg) or (ii) the s 1 protein inactivator BD1047 (1 mg/kg) with the active doses of ANAVEX1-41 (30, 100 mg/kg). The learning abilities were analyzed after 7 days using the Y-maze and passive avoidance procedures. As shown in Figure 8a , the muscarinic receptor antagonist attenuated the ANAVEX1-41 effect, nonsignificantly against the 30 mg/kg dose of ANAVEX1-41 and significantly against 100 mg/kg (F (6,119) ¼ 5.14, p ¼ 0.0001). The BD1047 treatment led to a similar effect (Figure 8b ). BD1047 attenuated the ANAVEX1-41 effect, nonsignificantly against the 30 mg/kg dose of ANAVEX1-41 and significantly against 100 mg/kg (F (6,114) ¼ 4.55, po0.001; Figure 8b ). In the passive avoidance test, scopolamine pretreatment also fully prevented the ANAVEX1-41 (100 mg/kg) effect, but not the ANAVEX1-41 (30 mg/kg) effect, similarly for latency (H ¼ 30.6, po0.0001; Figure 9a ) and animals-to-criterion (Figure 9b ). However, different results were obtained in the contextual memory procedure with BD1047. The s 1 protein inactivator significantly blocked the beneficial effect of 30 mg/kg ANAVEX1-41, both in terms of step-down latency (H ¼ 39.7, po0.0001; Figure 9c ) and percentage of animals-to-criterion. The compound only nonsignificantly attenuated the ANAVEX1-41 (100 mg/kg) effect, particularly in terms of percentage of animals-to-criterion (Figure 9d ), suggesting that protection through activation of s 1 protein is differentially effective on short-term and long-term memory mechanisms.
DISCUSSION
The first data in this study showed that ANAVEX1-41 attenuated the learning deficits observed 1 week after the central injection of Ab 25-35 peptide in mice. In the brain of rats or mice, Ab 25-35 peptide induces, after acute injection or chronic infusion, biochemical changes, morphological alterations, and behavioral impairments reminiscent of AD physiopathology. In particular, Ab 25-35 -treated rodents showed spontaneous alternation, passive avoidance, and water-maze learning deficits (Maurice et al, 1996; Delobette et al, 1997) clearly related to alterations in cholinergic and glutamatergic corticolimbic systems (Maurice et al, 1996; Olariu et al, 2001 ). ANAVEX1-41, administered before the behavioral procedures, reversed the Ab 25-35 -induced deficits with a very low active dose range because the maximum antiamnesic effect was measured at 10 mg/kg for both the short-term and longterm memory tests. This observation confirms that ANAVEX1-41 is a very potent antiamnesic drug. The compound acts as a s 1 protein activator, with a K i value of 44 nM (Espallergues et al, 2007) . Such pharmacological action is known to mediate antiamnesic effects, particularly against Ab 25-35 -induced learning impairments. Numerous s 1 protein activators including ( + )-SKF-10 047, ( + )-pentazocine, SA4503, or PRE-084 attenuated Ab 25-35 -induced learning impairments (Maurice et al, 1998; Meunier et al, 2006) . Indeed, activation of the s 1 protein rapidly results in amplification of Ca 2 + mobilization from intracellular stores, facilitating Ca 2 + -dependent intracellular pathways and activation of intracellular kinases (Morin-Surun et al, 1999; Hayashi and Su, 2001; Dong et al, 2005) . In turn, s 1 protein activators increase hippocampus glutamatergic transmission by facilitating glutamate release, activation of glutamate receptors and long-term potentiation (Monnet et al, 1992; Dong et al, 2005) . They may also directly facilitate cholinergic neurotransmission by inducing acetylcholine release in the Figure 5 Morphological analysis of astrocytic reaction using GFAP immunolabeling in Ab 25-35 -treated mice. Animals were treated i.p. with saline vehicle solution (V) or ANAVEX1-41 (100 mg/kg) and received no i.c.v. treatment (two left columns), ScAb (9 nmol; two central columns) or Ab 25-35 (9 nmol; two right columns) and were killed after 7 days for immunohistological analysis. Coronal 30 mm thick sections were stained with anti-GFAP antibody and several brain areas were visually analyzed. Representative microphotographs are shown in two cortical areas, the retrospenial granular basal cortex (RSGb; a-f) and S1 cortex forelimb region (S1FL; g-l), and two hippocampal formation areas, the CA1 (m-r) and CA3 (s-x). The pyramidal cell layers are indicated by asterisks. Arrows outlined densifications of astrocyte labeling. Abbreviations: Or, oriens layer; Rad, stratum radiatum. At least three slices per mice and four mice per conditions were analyzed. Scale bar in (a) ¼ 300 mm.
Protection by ANAVEX1-41 against Ab 25-35 toxicity V Villard et al hippocampus and cortex (Matsuno et al, 1995; Horan et al, 2002) . ANAVEX1-41, however, also acts as a muscarinic ligand. We have previously reported that the compound shows K i values in the low nanomolar range for muscarinic receptors subtypes (18-114 nM), with a profile by ascending order of potency: M 1 4M 3 4M 4 4M 2 (Espallergues et al, 2007) . All subtypes of muscarinic receptors are expressed in the hippocampus and cortex (Levey et al, 1995) and postsynaptic M 1 and autoreceptor M 2 subtypes have been shown to be crucially involved in learning and memory processes (Ghelardini et al, 1999 ; but see also Quirion et al, 1995; Miyakawa et al, 2001; Seeger et al, 2004) . Nonselective muscarinic antagonists, such as scopolamine and atropine, impair performance in various learning and memory tasks in rodents, including eight-arm radial maze learning (Eckerman et al, 1980) , contextual fear conditioning (Anagnostaras et al, 1995) , water-maze learning (Sutherland et al, 1982) , or passive avoidance (Espallergues et al, 2007) .
The combined activity of ANAVEX1-41 at s 1 protein and muscarinic receptors is expected to lead to synergistic effect on memory. Indeed, activation of the s 1 protein and M 2 autoreceptors antagonism by ANAVEX1-41 (Vamvakides, 2002; Espallergues et al, 2007) may facilitate Ca 2 + -dependent acetylcholine release from presynaptic terminals in the hippocampus and cortex, as shown with other compounds (Quirion et al, 1995; Matsuno et al, 1995; Horan et al, 2002) . As previously discussed (Espallergues et al, 2007) , it is obvious that, at the very low pharmacologically active doses (10-100 mg/kg) measured for ANAVEX1-41, the compound acts both as s 1 activator and muscarinic receptor ligand and provokes complex concomitant effects on neurotransmission that will affect: (i) acetylcholine release, by presynaptic s 1 protein-mediated and M 2 autoreceptor-mediated effects; (ii) phospholipase C activation induced by muscarinic receptor activation but amplified by s 1 protein-mediated activity; and (iii) IP 3 formation and activation of ER IP 3 receptors, again amplified by the s 1 protein activation. Noteworthy, the active dose shown by ANAVEX1-41 is unrelated to the drug in vitro affinities for either s 1 protein or muscarinic receptor subtypes. For comparison, PRE-084, a selective s 1 activator with a similar affinity of 44 nM (Su et al, 1991) , is antiamnesic at 0.5-1 mg/kg against Ab 25-35 -induced learning impairments (Meunier et al, 2006) . One of the most promising muscarinic compound, AF102B, inhibiting 3 H-quinuclidinyl benzilate binding with K i values in the 1-5 nM concentration range (Fisher et al, 1991) , is active at 1-5 mg/kg against the learning deficits induced in rats by bilateral i.c.v. injection of the cholinotoxin ethylcholine aziridinium ion (AF64A; Nakahara et al, 1989) . ANAVEX1-41, with a similar affinity for s 1 protein as PRE-084 and even lower affinities for muscarinic subtypes as AF102B, showed an in vivo activity at 10 mg/kg, ie, almost 100 times lower than the cited drugs. These data must be tempered after considering the protein binding and brain/plasma ratio in humans, but suggests strong synergic effects between the s 1 and muscarinic targets. The precise mechanism of action remains to be analyzed more adequately using in vitro preparations, but it clearly relies on facilitated Ca 2 + mobilization and activation of Ca 2 + -dependent intracellular signaling induced by muscarinic receptor and s 1 protein during learning-induced neuronal activation.
The second part of the study analyzed the neuroprotective potential of ANAVEX1-41 in Ab 25-35 -treated mice. For this purpose, the compound was administered at the same time as Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , ie, 7 days before the behavioral, morphological or biochemical analyses, a procedure known to allow the observation of neuroprotective effects for mixed cholinergic and s 1 drugs (Meunier et al, 2006) . The compound induced a bell shaped but significant prevention of Ab 25-35 -induced learning deficits, with an active dose about 100 mg/kg. At the morphological level, Ab 25-35 induced a limited but significant cell loss in the CA1 pyramidal cell layer of the hippocampus (Stepanichev et al, 2004 ) and a marked inflammation in corticolimbic structures that could be visualized by analyzing the GFAP immunolabeling in reactive astrocytes (Stepanichev et al, 2003; Klementiev et al, 2007) . Interestingly, although a significant cell loss could be measured in particularly vulnerable areas, like CA1 in mice, GFAP immunolabeling increased in a more diffuse manner, in structures associated with the amyloid deposits, as observed in the retrospenial granular basal cortex and oriens layer of the hippocampus. ANAVEX1-41, tested at 100 mg/kg, significantly attenuated the Ab 25-35 -induced cell loss in CA1 and increase in GFAP expression, as shown by Protection by ANAVEX1-41 against Ab 25-35 toxicity V Villard et al western blot. It appeared then that ANAVEX1-41 is able to counteract the morphological damages induced by amyloid toxicity in sensitive structures.
The neuroprotective effect of the compound was also tested using selected biochemical markers. First, Ab induces a strong oxidative stress, as observed in cell culture models (Behl et al, 1994) or in the hippocampus and cortex of rodents centrally injected with the peptides (Meunier et al, 2006 ). We therefore analyzed the level of lipid peroxidation in the hippocampus, 7 days after Ab 25-35 . Peroxynitrite anion, ONOO À , is formed from nitric oxide and superoxide anion during oxidative stress and is responsible for a widespread biological damage in the AD brains (Smith et al, 1997) . Ab 25-35 -induced formation of ONOO À could be indirectly indicated by the level of nitrated proteins, 5 days after peptide injection (Alkam et al, 2007) . Moreover, Ab-induced oxidative stress is because of production of reactive oxygen species by the mitochondria, by premature electron leakage to oxygen through the respiratory electron transport chain, and dysfunction of enzymes responsible for Protection by ANAVEX1-41 against Ab 25-35 toxicity V Villard et al limiting the superoxide production, such as NAPDHdependent oxidase, NADH-dependent diaphorase, and superoxide dismutase (Kim et al, 2003) . Several markers could be used to selectively assess the appearance of mitochondrial damage, such as release of cytochrome c into the cytosol or, as we analyzed, induction of caspase-9. Finally, we also analyzed the induction of caspase-3, known to be a key mediator of Ab-mediated apoptosis. Results
showed that ANAVEX1-41 blocked the Ab 25-35 -induced increase in lipid peroxidation, at 30 and 100 mg/kg, in the hippocampus. The compound also blocked the increase in protein nitration. This antioxidant effect, however, may not primarily involve the mitochondria because Ab 25-35 -induced increase in caspase-9 was not attenuated by ANAVEX1-41. Noteworthy, the s 1 protein is expressed at the surface of the mitochondria and at focal contacts between the ER and mitochondria (Hayashi and Su, 2007) . We have previously observed that the s 1 protein activator PRE-084 blocks the Ab 25-35 -induced increase in lipid peroxidation (Meunier et al, 2006) , suggesting that activation of the s 1 protein results in an antioxidant effect mediated at the mitochondrial level. Our biochemical data suggest that ANAVEX1-41 also induces a strong antioxidant effect that may, however, not primarily involve a protection of mitochondrial integrity through s 1 protein activation. Otherwise, oxidative stress has been shown to impair M 1 and M 2 muscarinic receptor signaling activity, through increased phosphorylation and sequestration (Mou et al, 2006) , an effect that may impede the pharmacological action of ANAVEX1-41 at muscarinic receptors. A precise mechanistic study has therefore to be carried out to identify the mechanism of the antioxidant action of ANAVEX1-41. The compound is nevertheless protective against the resulting apoptosis, as it blocked the induction of caspase-3. This observation could be considered as one of the cellular correlates of the protecting effect of ANAVEX1-41, already described at the morphological and behavioral levels.
The mechanism of the neuroprotective activity of ANAVEX1-41 is likely to involve, as detailed above regarding its antiamnesic action, a complex interaction between its muscarinic and s 1 targets. We observed that scopolamine or BD1047 could significantly inhibit the protective effect of ANAVEX1-41, at least in terms of learning deficits. A synergistic s 1 /muscarinic mechanism could also be evoked to account for the neuroprotective efficacy of ANAVEX1-41, in particular, through the phospholipase C involvement and regulation of intracellular Ca 2 + homeostasis. In summary, we reported that ANAVEX1-41, a new mixed muscarinic receptor ligand and s 1 protein activator, is a very active antiamnesic and neuroprotective drug against Ab 25-35 peptide-induced amnesia and toxicity in the mouse. Its similar efficacy at muscarinic and s 1 targets suggest a unique, concomitant action, most probably at the presynaptic and intraneuronal levels, on neurotransmitter release, activation of membrane receptors and intracellular transduction systems. 
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